Branched chain amino acids (BCAAs), including leucine, isoleucine, and valine, may potentially influence cancer progression by various mechanisms including its role in insulin resistance. However, the association of BCAAs with survival among patients with established colorectal cancer (CRC) remains unclear. We evaluated the associations between postdiagnostic BCAA intake with CRC-specific and overall-mortality among 1,674 patients with nonmetastatic CRC in the Nurses’ Health Study and the Health Professionals Follow-up Study. Patients completed a validated food frequency questionnaire. Multivariable hazard ratios (HRs) were calculated using Cox proportional hazards regression model after adjustment for tumor characteristics and potential confounding factors. Comparing the highest with the lowest quartile intake of postdiagnostic total BCAA, the multivariable HRs were 1.18 [95% confidence interval (CI), 0.75-1.85, P for trend=0.46 across quartiles] for CRC-specific mortality and 1.30 (95% CI, 1.01-1.69, P for trend=0.04) for all-cause mortality. The multivariable HRs (the highest vs. the lowest quartile) for all-cause mortality were 1.33 (95% CI, 1.03-1.73, Ptrend=0.02) for valine, 1.28 (95% CI, 0.99-1.66, P for trend=0.05) for leucine, and 1.25 (95% CI, 0.96-1.61, P for trend=0.06) for isoleucine. No statistically significant associations with each of the BCAA intake were observed for CRC-specific mortality (all P for trend>0.30). Our findings suggest positive associations between higher intake of dietary BCAAs and risk of all-cause mortality in CRC patients. These findings need to be confirmed and potential mechanisms underlying this association need to be elucidated. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
For latest news and updates